<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784445</url>
  </required_header>
  <id_info>
    <org_study_id>PEP 2013</org_study_id>
    <nct_id>NCT01784445</nct_id>
  </id_info>
  <brief_title>Post ERCP Pancreatitis Prevention in Average Risk Patients</brief_title>
  <official_title>Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Rijeka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Rijeka</source>
  <oversight_info>
    <authority>Croatia: HALMED (Croatian Agency for Drugs and Medicinal Products)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diclophenac potassium and ceftazidime are commercially available drugs that are used in
      various clinical situations. They are safe and known for years. Diclophenac potassium and
      Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis
      and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is
      currently standard treatment for prevention of (PEP) while ceftazidime is possible
      alternative treatment for patients with contraindications for nonsteroidal medicines. The
      aim of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study type:

      Interventional Allocation: Randomized Endpoint Classification: Efficacy Study Intervention
      Model: Parallel Assignment Masking: only Investigator Primary Purpose: Prevention Study
      Phase: Phase 4

      Conditions or Focus of the study: Post ERCP pancreatitis

      Intervention information

        -  Intervention Names ERCP

        -  Arm Information

             -  Arm 1:Ceftazidime

             -  Arm 2 (active comparator): Diclophenac potassium
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Time to discharge from hospital</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Influence of PEP severity on time to discharge from hospital</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Ceftazidime plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 g i.v. once daily 30 minutes prior to procedure Intervention ERCP plus glycerin suppository as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclophenac sodium plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg suppositories, once daily immediately prior to procedure Intervention ERCP plus 100 ml of saline as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure</description>
    <arm_group_label>Ceftazidime plus placebo</arm_group_label>
    <arm_group_label>Diclophenac sodium plus placebo</arm_group_label>
    <other_name>Fortaz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  o All patients undergone to ERCP irrespectively about the diagnosis

        Exclusion Criteria:

          -  o Unwillingness or inability to consent for the study

               -  Age &lt; 18 years

               -  Previous ERCP (papillotomy)

               -  Intrauterine pregnancy

               -  Breast feeding mother

               -  Allergy to Aspirin or NSAIDs and Ceftazidime

               -  NSAID use within 1 week (ASA 325 mg daily or less acceptable)

               -  Renal failure (Cr &gt; 1.4)

               -  Active or recent (within 4 weeks) gastrointestinal hemorrhage

               -  Existing acute pancreatitis (lipase peak) within 72 hours prior to ERCP

               -  Anticipated inability to follow protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Hauser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rijeka</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Centre</name>
      <address>
        <city>Rijeka</city>
        <state>Kresimirova 42</state>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goran Hauser, MD, PhD</last_name>
      <phone>385 98 18 20 726</phone>
      <email>ghauser@medri.hr</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Mikic, ass</last_name>
      <phone>385 51 658 122</phone>
      <email>interna-rijeka@kbc-rijeka.hr</email>
    </contact_backup>
    <investigator>
      <last_name>Goran Hauser, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 1, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Rijeka</investigator_affiliation>
    <investigator_full_name>Goran Hauser</investigator_full_name>
    <investigator_title>Goran Hauser, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Endoscopic Retrograde Cholangiopancreatography,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
